Last reviewed · How we verify
NCT06591650
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer
Phase 2 trial testing gemcitabine hydrochloride in Gallbladder Cancer Unresectable in 33 participants. Not yet recruiting.
15 March 2026
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 33 |
| Start date | 10 September 2024 |
| Primary completion | 15 March 2026 |
| Estimated completion | 15 September 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- gemcitabine hydrochloride — full drug profile →
- Cisplatin (cisplatin) — full drug profile →
- Nab-paclitaxel
- Durvalumab — full drug profile →
Conditions studied
- Gallbladder Cancer Unresectable — all drugs for Gallbladder Cancer Unresectable →
Sponsor
Fudan University
Who can join
18 and older, any sex, with Gallbladder Cancer Unresectable. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trail will evaluate the efficacy and safety of combining gemcitabine hydrochloride, cisplatin, nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation), with durvalumab in treating patients who have locally advanced or metastatic gallbladder cancer. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab is a type of drug called a monoclonal antibody, which selectively blocks PD-L1 binding to PD-1. This anti-PD-L1 treatment works by allowing the immune system to detect your cancer and reactivates the immune response.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Global gene expression landscape of gallbladder cancer and advances in targeted therapeutic strategies.
Choudhury S, Maiti A, Bandopadhyay A, Tripathi A, et al · · 2025 · cited 1× · PMID 41178912 · DOI 10.5306/wjco.v16.i10.111028
Verify or expand the search:
- PubMed search for NCT06591650
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of gemcitabine hydrochloride
Trials testing the same drug.
- NCT02479230 — Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast · Phase 1 · completed
- NCT02178436 — Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer · Phase 1, PHASE2 · completed
- NCT01770132 — Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer · Phase 1 · completed
- NCT01473940 — Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cann · Phase 1 · completed
- NCT01611662 — Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer · Phase 2 · terminated
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06591650 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06591650.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing